SG11201809229VA - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- SG11201809229VA SG11201809229VA SG11201809229VA SG11201809229VA SG11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA SG 11201809229V A SG11201809229V A SG 11201809229VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ucb
- rule
- freeze
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 November 2017 (16.11.2017) WIPO I PCT omit IIl mum o oimIE (10) International Publication Number WO 2017/194646 Al (51) International Patent Classification: A61K 39/395 (2006.01) A61K 9/08 (2006.01) A61K 9/19 (2006.01) A61K 47/26 (2006.01) (21) International Application Number: PCT/EP2017/061261 (22) International Filing Date: 11 May 2017 (11.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1608323.0 12 May 2016 (12.05.2016) GB (71) Applicant: UCB BIOPHARMA SPRL [BE/BE]; 60, Al- lee de la Recherche, 1070 Brussels (BE). (72) Inventors: YATES, Andrew Jeffrey; c/o IPD, UCB Cell- tech, 208 Bath Road, Slough Berkshire SL1 2DT (GB). MASSANT, Jan Ivo; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). (74) Agent: UCB INTELLECTUAL PROPERTY; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: PHARMACEUTICAL COMPOSITION Fig. 1 70 (57) : The present invention relates to pharmaceutical compositions comprising an antibody or a fragment thereof suitable for freeze-drying (i.e. lyophilizing) The pharmaceutical compositions, which comprise an antibody or an antigen-binding fragment thereof; from 1 % to 20% w/v sucrose; an amino acid or a mixture of amino acids; and surfactant, are provided as pharmaceutical compositions for freeze-drying; as freeze-dried (i.e. lyophilized) compositions which can be reconstituted into a solvent at the time of use or as reconstituted liquid formulations ready for administration. [Continued on next page] WO 2017/194646 Al MIDEDIMOMOIDEIROIDEMOMOIROMINIfillOINVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(1i)) of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1608323.0A GB201608323D0 (en) | 2016-05-12 | 2016-05-12 | Pharmaceutical compositions |
PCT/EP2017/061261 WO2017194646A1 (en) | 2016-05-12 | 2017-05-11 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809229VA true SG11201809229VA (en) | 2018-11-29 |
Family
ID=56320265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809229VA SG11201809229VA (en) | 2016-05-12 | 2017-05-11 | Pharmaceutical composition |
Country Status (17)
Country | Link |
---|---|
US (1) | US11407835B2 (en) |
EP (1) | EP3454899B1 (en) |
JP (1) | JP7126454B2 (en) |
KR (1) | KR102436694B1 (en) |
CN (1) | CN109069643A (en) |
AR (1) | AR108449A1 (en) |
AU (1) | AU2017264553A1 (en) |
BR (1) | BR112018072264A2 (en) |
CA (1) | CA3022124A1 (en) |
CL (1) | CL2018003178A1 (en) |
CO (1) | CO2018011733A2 (en) |
EA (1) | EA201892446A1 (en) |
GB (1) | GB201608323D0 (en) |
IL (1) | IL262654A (en) |
MX (1) | MX2018013215A (en) |
SG (1) | SG11201809229VA (en) |
WO (1) | WO2017194646A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
TW202003036A (en) * | 2018-03-23 | 2020-01-16 | 德商艾伯維德國有限及兩合公司 | Stable aqueous anti-TAU antibody formulations |
PE20212185A1 (en) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | FORMULATION OF THERAPEUTIC ANTIBODIES |
EP4117631A1 (en) * | 2020-03-11 | 2023-01-18 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
EP4337257A1 (en) * | 2021-05-12 | 2024-03-20 | AnaptysBio, Inc. | Antibody composition |
AU2022402319A1 (en) | 2021-12-01 | 2024-05-02 | Biogen Ma Inc | Formulations comprising fab-peg |
WO2023224112A1 (en) * | 2022-05-20 | 2023-11-23 | 株式会社ダイセル | Liquid pharmaceutical composition |
US11926669B2 (en) | 2022-05-30 | 2024-03-12 | Hanall Biopharma Co., Ltd. | Anti-FcRn antibody or antigen binding fragment thereof with improved stability |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04000747A (en) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Stable lyophilized pharmaceutical formulation of igg antibodies. |
CN101124245A (en) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
AU2007251122B2 (en) * | 2006-05-12 | 2013-01-10 | Bharat Biotech International Limited | A composition useful as a vaccine |
AR070315A1 (en) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | ANTIBODIES 1B20 ANTAGONISTS OF PCSK9 |
AR070316A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN) |
US20120114646A1 (en) * | 2009-06-18 | 2012-05-10 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
US8788028B2 (en) | 2010-07-28 | 2014-07-22 | Medtronic, Inc. | Parasympathetic stimulation to enhance tachyarrhythmia detection |
WO2012076670A2 (en) | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
MX341076B (en) | 2011-03-31 | 2016-08-04 | Merck Sharp & Dohme | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments. |
JOP20200043A1 (en) | 2011-05-10 | 2017-06-16 | Amgen Inc | Methods of treating or preventing cholesterol related disorders |
EP2830658B1 (en) * | 2012-03-26 | 2018-10-10 | Sanofi | Stable igg4 binding agent formulations |
US9592289B2 (en) * | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
US20150307606A1 (en) | 2012-12-13 | 2015-10-29 | Ashwin Basarkar | Lyophilized spherical pellets of anti-il-23 antibodies |
WO2015121318A1 (en) | 2014-02-12 | 2015-08-20 | Sanofi | Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations |
AU2015332151A1 (en) | 2014-10-18 | 2017-04-27 | Pfizer Inc. | Anti-IL-7R antibody compositions |
GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
-
2016
- 2016-05-12 GB GBGB1608323.0A patent/GB201608323D0/en not_active Ceased
-
2017
- 2017-05-11 AU AU2017264553A patent/AU2017264553A1/en not_active Abandoned
- 2017-05-11 JP JP2018559221A patent/JP7126454B2/en active Active
- 2017-05-11 EA EA201892446A patent/EA201892446A1/en unknown
- 2017-05-11 AR ARP170101248A patent/AR108449A1/en unknown
- 2017-05-11 US US16/300,522 patent/US11407835B2/en active Active
- 2017-05-11 SG SG11201809229VA patent/SG11201809229VA/en unknown
- 2017-05-11 EP EP17725544.5A patent/EP3454899B1/en active Active
- 2017-05-11 CA CA3022124A patent/CA3022124A1/en active Pending
- 2017-05-11 MX MX2018013215A patent/MX2018013215A/en unknown
- 2017-05-11 WO PCT/EP2017/061261 patent/WO2017194646A1/en unknown
- 2017-05-11 BR BR112018072264-2A patent/BR112018072264A2/en unknown
- 2017-05-11 KR KR1020187036132A patent/KR102436694B1/en active IP Right Grant
- 2017-05-11 CN CN201780028404.3A patent/CN109069643A/en active Pending
-
2018
- 2018-10-28 IL IL262654A patent/IL262654A/en unknown
- 2018-10-30 CO CONC2018/0011733A patent/CO2018011733A2/en unknown
- 2018-11-08 CL CL2018003178A patent/CL2018003178A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2018141591A (en) | 2020-06-15 |
WO2017194646A1 (en) | 2017-11-16 |
AR108449A1 (en) | 2018-08-22 |
CL2018003178A1 (en) | 2019-02-01 |
US11407835B2 (en) | 2022-08-09 |
MX2018013215A (en) | 2019-02-21 |
IL262654A (en) | 2018-12-31 |
US20200048346A1 (en) | 2020-02-13 |
JP7126454B2 (en) | 2022-08-26 |
AU2017264553A1 (en) | 2018-12-13 |
BR112018072264A2 (en) | 2019-02-12 |
RU2018141591A3 (en) | 2021-01-13 |
EP3454899B1 (en) | 2024-03-20 |
GB201608323D0 (en) | 2016-06-29 |
EP3454899A1 (en) | 2019-03-20 |
KR20190008320A (en) | 2019-01-23 |
CO2018011733A2 (en) | 2019-02-08 |
CA3022124A1 (en) | 2017-11-16 |
EP3454899C0 (en) | 2024-03-20 |
EA201892446A1 (en) | 2019-04-30 |
CN109069643A (en) | 2018-12-21 |
KR102436694B1 (en) | 2022-08-25 |
JP2019514998A (en) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201809229VA (en) | Pharmaceutical composition | |
SG11201908540PA (en) | Stable antibody formulation | |
SG11201810327XA (en) | Single domain serum albumin binding protein | |
SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201808242UA (en) | Methods for inhibiting angiogenesis in a subject in need thereof | |
SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations |